GLP-1, an incretin hormone, exerts anorexigenic effects by enhancing satiety and reducing gastric emptying, and has become a central focus in obesity treatment through GLP-1 receptor agonists [185,186]. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.